Fate Therapeutics Inc.

09/11/2024 | Press release | Distributed by Public on 10/11/2024 01:57

Fate Therapeutics Highlights Cancer selective, HER2 Targeting Profile of FT825 / ONO 8250 CAR T cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC[...]